8-K: Glucotrack to File US FDA IDE for CBGM Clinical Trial

Glucotrack, Inc. announced plans to submit an Investigational Device Exemption to the FDA in Q2 2026 for its novel continuous blood glucose monitoring technology, following successful international clinical trials.

Summary

• Glucotrack plans to submit an Investigational Device Exemption (IDE) to the U.S. FDA in Q2 2026 for its novel continuous blood glucose monitoring (CBGM) technology.
• This follows critical operational milestones achieved in 2025, including the completion of a first-in-human study in Brazil and the initiation of a follow-up study in Australia.
• The Brazil study, conducted between December 13, 2024, and January 31, 2025, included ten participants and demonstrated excellent accuracy with a Mean Absolute Relative Difference (MARD) of 7.7% across 122 matched pairs and a 99% data capture rate, with no procedure or device-related serious adverse events.
• The CBGM measures glucose directly from blood, eliminating the typical lag time associated with traditional continuous glucose monitoring systems.
• U.S. market research indicates an unmet need for a fully implantable CBGM solution, and a clear U.S. reimbursement pathway has been identified.
• The company has established a dual-source U.S. manufacturing strategy with two qualified contract manufacturing partners and assembled a seasoned management team.
• Three critical patents relating to the CBGM platform (proprietary sensor chemistry, intravascular lead design, and low-power electronics) were awarded in October and November 2025.
• A U.S. clinical trial site has been secured, and a Clinical Research Organization (CRO) experienced with diabetes Medtech has been engaged to manage and conduct the study, which is expected to initiate in the second half of 2026, subject to FDA IDE approval.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive update, demonstrating significant progress in clinical development, intellectual property, and market readiness for a differentiated medical device, positioning the company for key regulatory milestones.

Positives

• Successful completion of first-in-human study in Brazil with excellent accuracy (MARD of 7.7%) and 99% data capture rate.
• No procedure or device-related serious adverse events reported in the Brazil study, indicating a strong safety profile.
• The CBGM technology measures glucose from blood, eliminating typical lag time of interstitial fluid-based CGMs.
• U.S. market research confirms an unmet need for a fully implantable CBGM solution.
• Identified a clear U.S. reimbursement pathway supporting a compelling economic profile.
• Established a dual-source U.S. manufacturing strategy with two qualified partners.
• Assembled a seasoned management team with deep experience from industry leaders such as Dexcom, Abbott, Senseonics, and Medtronic.
• Awarded three critical patents in October and November 2025, strengthening intellectual property for the CBGM platform.
• Secured a U.S. clinical trial site and engaged an experienced Clinical Research Organization (CRO) for the upcoming U.S. study.

Risks

• Ability to raise additional capital to finance operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise).
• Risks relating to the receipt and timing of regulatory approvals, including U.S. Food and Drug Administration approval.
• Risks relating to enrollment of patients in, and the conduct of, clinical trials.
• Risks relating to future distribution agreements.
• Risks relating to the ability to hire and retain qualified personnel, including sales and distribution personnel.
• Actual results may differ materially from forward-looking statements due to various factors.

Future Outlook

Glucotrack expects to submit its Investigational Device Exemption (IDE) to the FDA in Q2 2026 and, pending FDA approval, aims to initiate its U.S. clinical study in the second half of 2026. The company anticipates its differentiated technology has the potential to deliver meaningful, scalable impact for millions of patients in a rapidly growing market segment.

Management Comments

• "In 2025 we made meaningful progress in advancing the development of our fully implantable continuous blood glucose monitoring technology and strengthening Glucotracks foundation."
• "The completion of our first-in-human study in Brazil and initiation of our follow up study in Australia enables us to advance toward our U.S. clinical program."
• "With trial infrastructure in place and product enhancements completed, we are prepared to initiate the study, pending FDA approval."
• "Our research indicates that our differentiated technology has the potential to deliver meaningful, scalable impact for millions of patients."
• "We are extremely proud of the accomplishments we achieved as a team in 2025, and we are prepared to execute further on the development of our first-to-market CBGM system to meet the needs of the millions of people living with diabetes in the US alone."

Industry Context

StockSavvy.ai notes that the continuous glucose monitor (CGM) market is one of the fastest-growing and most dynamic segments within the global diabetes healthcare market. Glucotrack's fully implantable CBGM, which measures glucose directly from blood, represents a significant differentiation from existing subcutaneous CGMs (e.g., Dexcom, Abbott's FreeStyle Libre, Senseonics' Eversense) by potentially eliminating lag time and offering a longer sensor longevity (3 years) without an on-body wearable component, addressing an identified unmet need.

Comparison to Industry Standards

• Glucotrack's Brazil study achieved a Mean Absolute Relative Difference (MARD) of 7.7%. This compares favorably to many commercially available continuous glucose monitors (CGMs), which typically report MARD values ranging from 8% to 10% in clinical settings. For instance, Dexcom G6 has reported MARDs around 9%, and Abbott FreeStyle Libre 2 around 9.3%. Senseonics' Eversense, another implantable device, has reported MARDs in a similar range.
• The 99% data capture rate is a strong indicator of reliability, aligning with high-performing industry standards.
• The absence of procedure or device-related serious adverse events in the first-in-human study is a positive safety signal, crucial for an implantable device, and is a key benchmark for early-stage medical device trials.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if the company successfully navigates regulatory approvals and commercializes its differentiated CBGM technology.
• Patients (with diabetes): Potential for a novel, long-term, fully implantable continuous blood glucose monitoring system that eliminates lag time and on-body wearables, addressing an unmet need for improved diabetes management.
• Healthcare Providers: Introduction of a new, potentially superior tool for managing diabetes, offering better data and patient compliance.
• Employees: Continued employment and potential growth opportunities as the company advances its product development and commercialization efforts.

Next Steps

• Submit Investigational Device Exemption (IDE) to the U.S. FDA in Q2 2026.
• Initiate the U.S. clinical study in the second half of 2026, subject to FDA IDE approval.
• Continue discussions with the FDA regarding the planned U.S. clinical trial program.
• Further execute on the development of the first-to-market CBGM system.

Key Dates

Recommendation

The successful completion of initial human trials with strong accuracy (MARD 7.7%) and safety data, coupled with the imminent FDA IDE submission and planned US clinical trial, represents a significant de-risking event for Glucotrack's novel implantable CBGM technology. The identified unmet market need, clear reimbursement pathway, robust manufacturing strategy, and strengthened IP portfolio position the company for substantial future growth in a rapidly expanding market. While regulatory approval and capital raising remain risks, the current progress suggests a strong upside potential for long-term investors.

Keywords

Glucotrack, GCTK, Continuous Blood Glucose Monitoring, CBGM, FDA IDE, Clinical Trials, Diabetes, Medical Technology, Implantable Device, Glucose Monitoring, Patents, Medtech